Clinical review report: Latanoprostene bunod (Vyzulta) (Bausch Health Canada Inc.)
The objective of this review was to perform a systematic review of the beneficial and harmful effects of latanoprostene bunod 0.024% ophthalmic solution for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
August 2019, 2019
|
Edition: | Version: final (with redactions) |
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references